Celldex Therapeutics, Inc. (NASDAQ:CLDX) CFO Samuel Bates Martin Sells 17,172 Shares

Celldex Therapeutics, Inc. (NASDAQ:CLDX) CFO Samuel Bates Martin sold 17,172 shares of the business’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $35.42, for a total transaction of $608,232.24. Following the sale, the chief financial officer now directly owns 28,125 shares in the company, valued at approximately $996,187.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Samuel Bates Martin also recently made the following trade(s):

• On Thursday, May 30th, Samuel Bates Martin sold 35,000 shares of Celldex Therapeutics stock. The stock was sold at an average price of $34.05, for a total transaction of $1,191,750.00.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX traded down $0.16 during midday trading on Tuesday, hitting $34.75. The company had a trading volume of 400,758 shares, compared to its average volume of 795,506. Celldex Therapeutics, Inc. has a 12-month low of $22.11 and a 12-month high of $53.18. The company has a fifty day moving average of $37.66 and a two-hundred day moving average of $39.04. The company has a market cap of $2.29 billion, a price-to-earnings ratio of -12.50 and a beta of 1.48.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. Research analysts expect that Celldex Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of institutional investors have recently bought and sold shares of CLDX. New York State Common Retirement Fund grew its holdings in Celldex Therapeutics by 3.6% during the 3rd quarter. New York State Common Retirement Fund now owns 23,780 shares of the biopharmaceutical company’s stock valued at $654,000 after buying an additional 821 shares in the last quarter. Swiss National Bank lifted its stake in shares of Celldex Therapeutics by 1.0% in the 3rd quarter. Swiss National Bank now owns 88,300 shares of the biopharmaceutical company’s stock valued at $2,430,000 after purchasing an additional 900 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Celldex Therapeutics by 3.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,547 shares of the biopharmaceutical company’s stock worth $9,950,000 after purchasing an additional 10,818 shares during the period. Deutsche Bank AG increased its position in shares of Celldex Therapeutics by 9.4% during the 3rd quarter. Deutsche Bank AG now owns 37,221 shares of the biopharmaceutical company’s stock valued at $1,024,000 after purchasing an additional 3,213 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in Celldex Therapeutics by 4.2% during the 3rd quarter. Rhumbline Advisers now owns 76,674 shares of the biopharmaceutical company’s stock valued at $2,110,000 after buying an additional 3,121 shares during the period.

Analyst Ratings Changes

A number of analysts have commented on the company. Wolfe Research started coverage on Celldex Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Monday, June 3rd. Stifel Nicolaus assumed coverage on shares of Celldex Therapeutics in a report on Tuesday. They set a “buy” rating and a $58.00 price target on the stock. Guggenheim lifted their price target on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $62.17.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.